OncLive TV

Vernon Sondak, MD, discusses the importance of accurately distinguishing advanced cutaneous squamous cell carcinoma from basal cell carcinoma.

Balazs Halmos, MD, MS, highlights the significance of the accelerated approval of zongertinib in HER2 TKD–mutated non–small cell lung cancer.

Richard Kim, MD, discusses how data from the phase 3 POD1UM-303 trial inform the use of retifanlimab plus chemotherapy in frontline metastatic SCAC.

Igor Makhlin, MD, discusses the evolving role of FES-PET/CT as a tool to aid in the diagnosis and management of estrogen receptor–positive breast cancer.

John Moroney, MD, and Katherine Kurnit, MD, MPH, discuss the importance of clinical trials in gynecologic oncology.

Ranee Mehra, MD, discusses the FDA breakthrough therapy designation for amivantamab and hyaluronidase for patients with recurrent or metastatic HNSCC.

Linda T. Vahdat, MD, MBA, discusses the design of a phase 2 trial of copper depletion as a strategy to prevent metastasis in high-risk TNBC.

Tycel Phillips, MD, discusses the next steps mantle cell lymphoma research needs to take and makes suggestions for future clinical trial designs.

Mehmet Bilen, MD, discusses considerations for treatment selection in mCSPC based on data from a real-world study of apalutamide vs darolutamide.

Linda T. Vahdat, MD, MBA, discusses the scientific rationale for therapeutic copper depletion to prevent triple-negative breast cancer metastasis.

Jasleen Pannu, MBBS, discusses the importance of proactive biomarker ordering and close multidisciplinary collaboration in optimal lung cancer care.

Cynthia A. Schandl, MD, PhD, discusses the role of the pathologist in expediting biomarker-driven treatment decisions in lung cancer care.

Gurbakhash Kaur, MD, discusses the potential role of CELMoDs in the multiple myeloma treatment paradigm.

Linda T. Vahdat, MD, MBA, discusses the rationale for depleting copper levels as a form of high-risk triple-negative breast cancer management.

Mehmet Bilen, MD, discusses findings from a real-world analysis of apalutamide vs darolutamide in mCSPC.

Alexandra Rojek, MD, discusses efforts to improve the safety and efficacy of CAR T-cell therapies in lymphoma through ongoing research.

Mehmet Bilen, MD, discusses the rationale for a real-world analysis of apalutamide vs darolutamide in mCSPC.

Stacy Tessler Lindau, MD, MA, discusses potential next steps for the Bionic Breast project.

Joseph Dominic Femino, MD, discusses the lack of adjuvant options for chondrosarcoma and the promise of IDH inhibitors like ivosidenib.

Sonali M. Smith, MD, discusses efforts to translate benefit with CAR T-cell therapy from hematologic malignancies to the solid tumor space.

Stacy Tessler Lindau, MD, MA, discusses which patients would be strong fits for the Bionic Breast project.

Experts preview key bladder, kidney, and prostate cancer trials to watch at the 2026 Genitourinary Cancers Symposium.

Joseph Dominic Femino, MD, discusses breakthroughs in limb salvage surgery, including innovative ways to reconstruct bone and joints after resection.

Christopher Lieu, MD, discusses clinical objectives for third-line mCRC management and patient-specific factors guiding therapeutic strategy.

Stacy Tessler Lindau, MD, MA, discusses the design of the Bionic Breast project at University of Chicago.

Martha Welman, MD, discusses several personalized health care disparity interventions that have been shown to increase access to breast cancer screening.

Martha Welman, MD, discusses findings from a study of strategic screening initiatives aimed at reducing breast cancer diagnostic disparities.

Stacy Tessler Lindau, MD, MA, discusses the primary goals of the Bionic Breast project.

Benjamin A. Weinberg, MD, FACP, discusses how biomarker status guides third-line treatment selection in mCRC.

Stacy Tessler Lindau, MD, MA, outlines prior research that informed the initiation of the Bionic Breast project at University of Chicago.